SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is drawing attention after falling to reported record lows, with traders pointing to concerns about Trump Medias losses, dilution, weak Truth Social engagement and Trumps declining approval ahead of the midterms. The discussion is overwhelmingly bearish, though some traders frame the drop as a buying opportunity.

QXO, Inc. is a publicly traded distributor of roofing, waterproofing and complementary building products in the United States. It plans to become tech-enabled in the building products distribution industry and generate outsized value for shareholders. The company was founded on October 3, 2002, and is headquartered in Greenwich, CT.

QXO Inc.

QXO is drawing attention for its prolonged selloff and repeated lows, amid analyst target cuts and concerns about weak roofing and housing demand, elevated rates, and the debt and dilution tied to its acquisition-led expansion. Traders are split between expecting further declines and viewing the depressed valuation as an opportunity if the roll-up strategy delivers integration and margin progress.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

Concerns about CoreWeaves debt burden, bond-market stress and ability to finance its AI data-center expansion dominate the discussion, while Goldman Sachs Buy upgrade has fueled hopes for a rebound. Traders remain divided: bulls call the selloff overdone and anticipate a squeeze, while bears say financing risks and weak price action outweigh the upgrade.

MARA Holdings, Inc. is a digital asset technology company, which engages in mining cryptocurrencies with a focus on the Bitcoin ecosystem. It also deals with owning and operating bitcoin mining facilities or data centers, selling proprietary software or technology to third parties operating in the Bitcoin ecosystem, offering advisory and consulting services to support Bitcoin mining ventures in domestic and international jurisdictions, and generating electricity from renewable energy resources or methane gas capture to power Bitcoin mining projects. The company was founded on February 23, 2010 and is headquartered in Hallandale Beach, FL.

MARA Holdings Inc.

Marathon Digital Holdings Inc

MARAs prolonged selloff and sharp underperformance despite Bitcoin holding near elevated levels dominate discussion, with traders blaming weak sentiment and the lack of signed AI/data-center tenant deals. Bearish frustration over management and the unproven pivot competes with dip-buying and speculation that a lease announcement or Bitcoin rebound could lift shares.

AXT, Inc. engages in the design, development, manufacture and distribution of compound and single element semiconductor substrates. It also sells specialty material substrates and raw materials used to make substrates and other related products. The company was founded by Morris S. Young and Davis Zhang in 1986 and is headquartered in Fremont, CA.

AXT Inc

AXTI is drawing attention for its sharp, volatile moves and its role as an indium phosphide substrate supplier for AI data-center optics. Bulls point to AI-driven demand and recent business momentum, while bears argue the shares are overvalued and flag China-related supply risks; the debate is amplified by heavy trading around earnings and technical levels.

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for hematologic diseases. It assembles a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. The company was founded in October 2017 and is headquartered in Watertown, MA.

Disc Medicine Inc

Disc Medicine shares are surging after bitopertin met all primary and secondary endpoints in the Phase 3 APOLLO trial for erythropoietic protoporphyria, addressing the FDAs earlier concerns about clinical benefit after a prior rejection. Traders are debating whether the move has room to extend, including speculation about short covering, versus profit-taking and resistance; FDA approval is still pending, and some raise concerns about dizziness reported in the trial.

Sunrun, Inc. engages in the design, development, installation, sale, ownership, and maintenance of residential solar energy systems. It sells solar service offerings and installs solar energy systems for homeowners. Customers can access its products through three channels: direct-to-consumer, solar partnerships, and strategic partnerships. The company was founded by Edward Harris Fenster, Robert Nat Kreamer, and Lynn Michelle Jurich in January 2007 and is headquartered in San Francisco, CA.

Sunrun Inc

Sunruns push to monetize its residential solar-and-battery network for distributed power and AI computing is a major topic, with traders debating the potential of its pilot and partnerships against the stocks persistent weakness. Bulls also point to heavily short positioning, while bears cite financing and interest-rate sensitivity and broader solar-sector pressure.

Annaly Capital Management, Inc. engages in the investment and financing of residential and commercial assets. It operates through the following segments: Agency, Residential Credit, Mortgage Servicing Rights (MSR), and Corporate and Other. The Agency segment invests in agency mortgage-backed securities. The Residential Credit segment is involved in non-agency residential mortgage assets within securitized products and whole loan markets. The MSR segment provides the right to service residential mortgage loans in exchange for a portion of the interest payments made on the loans. The company was founded by Michael A. J. Farrell and Wellington Jamie Denahan-Norris on November 25, 1996 and is headquartered in New York, NY.

Annaly Capital Management Inc

NLY is drawing attention after sliding to reported 52-week lows alongside other mortgage REITs, with traders tying the weakness to interest-rate and mortgage-bond repricing concerns. Some view the selloff as a chance to buy for the high dividend, while others worry that persistent rate pressure could weigh further on the shares and payout.

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Bitcoins volatile swings and the rebound in crypto-linked stocks are driving attention to Coinbase, with traders frequently debating whether COIN is lagging the crypto market. Sentiment is split between optimism ahead of Q3 earnings and skepticism over the stocks sharp reversals and weak relative performance.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Morgan Stanley naming Amazon a top pick, citing AWS growth and AI opportunities, is the main catalyst behind the sharp rally. Traders are broadly upbeat, while some question whether the upgrade-driven move will hold and remain cautious about capex and the upcoming earnings report.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Spruce Biosciences to Participate in the Craig-Hallum Biotech Catalyst Conference

Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will participate...

Spruce Biosciences Announces Presentation of MPS IIIB Natural History Data at the 55th Child Neurology Society Annual Meeting

Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that data from Study 250-902 (NCT03227042), a prospective, multicenter...

Spruce Biosciences to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at...

Spruce Biosciences Announces Launch of MPS3BStudy.com

Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the launch of MPS3BStudy.com, a dedicated online resource for families and...

Spruce Biosciences Q2 Loss Widens; Names Adrian Quarterl CMO, Jessica Cohen VP - Clinical

(RTTNews) - Spruce Biosciences, Inc. (SPRB), reported a deeper second-quarter loss on Wednesday, as operating expenses weighed on results and net loss per share nearly doubled from a year earlier...

Spruce Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today reported financial results for the second quarter ended June 30, 2026, and provided...

Cure Sanfilippo Foundation and National MPS Society Make $5.5 Million Strategic Investment in Spruce Biosciences

Spruce Biosciences, Inc. (Nasdaq: SPRB) a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that Cure Sanfilippo Foundation and the National MPS Society have agreed to make a...

Spruce Biosciences Appoints Jessica Cohen Pfeffer, M.D., as Vice President, Clinical Development

Spruce Biosciences, Inc. (Spruce Biosciences or Spruce) (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the appointment of Jessica Cohen Pfeffer, M.D., as...

Spruce Biosciences Appoints Adrian Quartel, M.D., FFPM, as Chief Medical Officer

Spruce Biosciences, Inc. (Spruce Biosciences or Spruce) (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the appointment of Adrian Quartel, M.D., FFPM, as...

Spruce Biosciences to Participate in the B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit

Spruce Biosciences, Inc. is a biopharmaceutical company, which engages in developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. The company was founded on November 13, 2014 and is headquartered in South San Francisco, CA.

Spruce Biosciences Inc

SPRB Stock Drops After Company Pushes Back Application Submission Timeline For Experimental Sanfilippo Syndrome Therapy 

Equity

Bullish Sentiment

<ul class="summary-bullets"><li>The company had previously said that it expects to submit an application for approval of the therapy in the first quarter of 2026.</li><li>In the December meeting with the FDA, the company discussed its clinical data and regulatory strategy.&nbsp;</li><li>In the second meeting, in January, it discussed chemistry, manufacturing, and controls (CMC) requirements.</li></ul>Shares of Spruce Biosciences, Inc. (SPRB) fell 8% on Wednesday after the company pushed back on its timeline to submit an application to the U.S. Food and Drug Administration seeking approval for its enzyme replacement therapy in patients with Sanfilippo Syndrome Type B.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20260218269143/en/Spruce-Biosciences-Announces-Positive-Type-B-Meetings-with-U.S.-FDA-for-TA-ERT-for-the-Treatment-of-Sanfilippo-Syndrome-Type-B-MPS-IIIB">said</a> that it completed two meetings with the FDA regarding its planned upcoming biologics license application (BLA) submission for tralesinidase alfa enzyme replacement therapy (TA-ERT) in the treatment of Sanfilippo syndrome type B.While the first meeting was held in Dec. 2025, the second was held in Jan. 2026. In the December meeting, the company discussed its clinical data and regulatory strategy, while in the second meeting, it discussed chemistry, manufacturing, and controls (CMC) requirements.The company now anticipates making the submission for TA-ERT in the fourth quarter of 2026 to accommodate the clinical and other requirements flagged by the FDA in the meetings. Spruce Biosciences had previously said that it expects to submit an application for approval of the therapy in the first quarter of 2026.<h2 class="st-heading-2">About Sanfilippo syndrome type B</h2>Sanfilippo syndrome type B (MPS IIIB) is a rare, inherited lysosomal storage disease caused by a deficiency in the enzyme alpha-N-acetylglucosaminidase, leading to the accumulation of heparan sulfate in cells, particularly neurons. It causes progressive neurological symptoms like cognitive and developmental impairment, hyperactivity with aggressive and destructive behavior, delayed speech, hearing loss, and motor skill deficits.Tralesinidase Alfa Enzyme Replacement Therapy is intended as an enzyme replacement therapy for the treatment of patients with MPS IIIB.“While the timing of our submission is now expected in the fourth quarter of this year, we believe in the strength of our long-term data for TA-ERT which demonstrates that reductions in CSF HS-NRE are associated with meaningful clinical benefits across cognition, communication, and motor skill acquisition,” CEO Javier Szwarcberg said.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around SPRB stock stayed within the ‘bullish’ territory over the past 24 hours, while message volume remained at ‘high’ levels.<a href="https://stocktwits.com/symbol/SPRB">SPRB stock</a> has gained nearly 372% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/why-did-mbrx-stock-climb-today/cZR0CkIR4vA">Why Did MBRX Stock Climb 14% Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

ADIL’s stock has declined 75% over the past 12 months.

Spruce Biosciences now anticipates making the submission for TA-ERT in the fourth quarter of 2026 to accommodate the clinical and other requirements flagged by the FDA in meetings.

Vanguard Extended Market ETF

$SPCX

$NFLX

$TSLA

$META

Which earnings release are you most looking forward to this week: $SPCX, $NFLX, $TSLA, or $META? Drop a comment for others.

Current Price	$40.34
Prev Close	$39.65
Open	$40.91
Dividend Yield	0.00%
50-Day Moving Average	$51.10
Beta	1.41
Avg. Volume	110,289.79
PE Ratio	-0.97

52-Week High	$154.95
52-Week Low	$38.06
Market Capitalization	$113.95M
EPS (Annual)	-$50.83
Price to Book	1.30
Revenue Per Employee	$0.00

Feed

News

Sentiment

Fundamentals

Info

SPRB Fundamentals